Theseus is led by targeted oncology pioneers with a proven track record in developing and commercializing targeted cancer therapeutics.

Iain D. Dukes, D.Phil., is a Venture Partner with OrbiMed Healthcare Fund Management. Iain also serves on the Board of Lion Biotechnologies. Most recently Iain was a Senior Vice President, Business Development & Licensing Merck where he oversaw all licensing deals for Merck Research Laboratories, including external research, out-licensing, regional deals and academic alliances. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, he served as Vice President of External Research and Development at Amgen. He has also held positions as President and CEO of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. from the University of Oxford where he also received a B.A. in Jurisprudence.

Tim Clackson, Ph.D., is President and Chief Executive Officer of Theseus Pharmaceuticals. Tim most recently served as President and Chief Technology Officer at Xilio Therapeutics, a privately held oncology company developing tumor-selective immunotherapies, where he led the development of the company’s technology and product strategy. From 1994 to 2018, Tim was with ARIAD Pharmaceuticals, where he was President of Research & Development and Chief Scientific Officer. He played a key role in the company’s evolution from early research to a global commercial oncology company, and its subsequent acquisition by Takeda. He led the multi-disciplinary R&D team that internally discovered and developed five clinical-stage product candidates, including ICLUSIG® (ponatinib), approved for patients with treatment-resistant Ph+ leukemias; ALUNBRIG® (brigatinib), approved for ALK+ non-small cell lung cancer (NSCLC); and EXKIVITY® (mobocertinib), approved for EGFR Exon20 insertion+ NSCLC. Prior to ARIAD, Tim was a postdoctoral research fellow at Genentech. He received his Ph.D. in Biology from the University of Cambridge, and his B.A. in Biochemistry from the University of Oxford. Tim serves as a director on the boards of Forma Therapeutics, Elevation Oncology and the Massachusetts Biotechnology Council (MassBio).

Carl L. Gordon, Ph.D., CFA, is a founding Partner and Co-Head of Global Private Equity at OrbiMed Healthcare Fund Management. For the last six years (2014 to 2019) Forbes^® Magazine named Dr. Gordon one of the top 100 venture capitalists in the world when it placed him on the "Forbes Midas List.” He received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and a B.A. from Harvard College, and was a Fellow at The Rockefeller University from 1993 to 1995.

Don Hayden is an accomplished biopharmaceutical executive and board member, having served earlier in his career at the highest levels in big pharma and thereafter as Chair or Director of multiple innovative biotechnology companies. He is passionate, knowledgeable, and conversant in the world of drug discovery and development, and he has helped successfully build multiple biotechnology companies by developing innovative business strategies, assembling high-performance teams, guiding organizations through key transformations, and mentoring senior leaders. During his 25-year career at Bristol-Myers Squibb, Mr. Hayden held a series of key leadership roles such as President of Global Pharmaceuticals, Executive Vice President and President of the Americas, Executive Vice President of the Health Care Group, President of Oncology and Immunology, and Senior Vice President of Worldwide Franchise Management and Business Development. At BMS, he consistently drove high levels of strategic change, superior business performance and successful development of future leaders. Since leaving Bristol-Myers Squibb, Mr. Hayden has dedicated his career to building high science biotechnology companies both private and public. He has served as Board Chair at a wide range of companies, including REGENXBIO, Amicus Therapeutics, Insmed, Vitae Pharmaceuticals, Gloucester Pharmaceuticals, and Dimension Therapeutics. From early-2019 until mid-2021, he served as Chair and CEO of the oncology cell therapy company WindMIL Therapeutics. He continues to serve as Chair of Otsuka America Pharmaceuticals and Avanir Pharmaceuticals. Mr. Hayden received an M.B.A. from Indiana University and his undergraduate degree from Harvard University.

Dr. Michael Rome is Managing Director at Foresite Capital, where he co-leads the therapeutics investing practice. Michael is a board director at Kinnate Biopharma, Pharvaris, and Remix Therapeutics, with board observer roles (past and present) at Turning Point Therapeutics, Maze Therapeutics, PACT Pharma, and Nurix Therapeutics. Michael served as Vice President for Foresite Development Corporation (FSDC) and has led investments in several public companies across the portfolio. Prior to Foresite Capital, he was an analyst at DAFNA Capital Management, covering and formulating investment ideas for small/mid-cap biotech companies. Michael previously worked in early-stage drug development for an academic start-up out of the California NanoSystems Institute at UCLA. He received his Ph.D. in Biochemistry from Caltech as an NSF graduate research fellow, and his B.S. in Molecular, Cell and Developmental Biology from UCLA. He has more than 12 years of experience as a research scientist and has authored numerous publications in biomedical research journals.

Dr. Stein has served as a member of our Board of Directors since October 2022. Dr. Stein currently serves as Executive Vice President, Chief Medical Officer of Incyte Corporation. Dr. Stein joined Incyte as Senior Vice President and Chief Medical Officer in March 2015, and has over 15 years of experience in clinical development and regulatory interactions. Dr. Stein joined Incyte from Novartis Pharmaceuticals Corporation, where he most recently served as Senior Vice President, U.S. Clinical Development & Medical Affairs at Novartis Oncology. Dr. Stein previously worked at GlaxoSmithKline as Vice President, Global Oncology, Clinical Development and as Head of Medicines Development for Hematology and Supportive Care. Dr. Stein earned his M.D. from the University of Witwatersrand in Johannesburg, South Africa.

Kathy Yi, M.B.A. has served as a member of our board of directors since June 2021. Ms. Yi serves as Chief Operating Officer, Affini-T Therapeutics. Previously, Ms. Yi served as Chief Financial Officer of Cerevel Therapeutics Holdings, Inc. (Nasdaq: CERE) from June 2019 to September 2021, and Executive Vice President, Chief Financial Officer and Secretary of Sangamo Therapeutics, Inc. (Nasdaq: SGMO), from February 2017 to June 2019. Prior to Sangamo Therapeutics, Ms. Yi was Head of Finance at Novartis Pharmaceutical Corporation (NYSE: NVS) from February 2014 to February 2017. From 2007 to 2014, Ms. Yi held various financial management positions of increasing seniority at Life Technologies Corp., which was acquired by Thermo Fisher Scientific in 2014, including Finance Leader, Corporate FP&A from 2012 to 2014, Director of Finance, M&A/Corporate Development, from 2010 to 2012, and Director of Finance, Global Manufacturing Operations, from 2007 to 2010. From 2001 to 2007, Ms. Yi held increasing roles of responsibilities in corporate finance at Intel Corporation. Ms. Yi holds a Bachelor of Science in Chemical Engineering from the University of California at Berkeley and a Master of Business Administration from Columbia Business School. We believe Ms. Yi is qualified to serve on our board of directors due to her extensive business, financial and accounting experience as an executive in the pharmaceutical industry.